J.david Gladstone Institutes

J. David Gladstone Institutes, a non-profit biomedical research organization based in San Francisco, California, operates as a federal grant recipient conducting foundational and translational research across neuroscience, virology, cardiovascular disease, aging, and immunology. The institute competes in full-and-open federal research grant competitions and does not hold contracts as a prime or subcontractor; its federal footprint is entirely grant-based, spanning 306 prime grants and 104 sub-award participations across 36 federal agencies, with particular concentration in NIH programs.

Gladstone's customer concentration is dominated by the National Institutes of Health. The top five NIH Institutes and Centers account for approximately 65% of awards by count: the National Institute on Aging (88 awards), a roll-up of NIH programs (71 awards), the National Institute of Allergy and Infectious Diseases (54 awards), the National Institute of Neurological Disorders and Stroke (30 awards), and the National Heart Lung and Blood Institute (23 awards). The Veterans Integrated Service Network 21 accounts for 6 awards ($84 thousand combined value), primarily small purchase orders for flow cytometry and core laboratory services delivered to the VA San Francisco Medical Center; these sole-source arrangements reflect the VA's reliance on Gladstone's specialized analytical expertise.

Gladstone's research portfolio centers on concrete disease mechanisms and therapeutic discovery. In neurodegenerative disease, the institute holds project grants investigating Alzheimer's disease pathogenesis through mechanistic lenses—APOE4-driven metabolic dysfunction, tau-related network hyperexcitability, vascular amyloid angiopathy, and genetic susceptibility through the MAPT locus (example: $1.731 million NIA award to conduct genetic dissection of 17Q21.31 MAPT locus through November 2030). In infectious disease, particularly HIV, recent work includes characterization of transcriptionally-active HIV reservoir cells ($2.047 million NIAID award for the Phaige Therapy Center developing AI-guided bacteriophage therapeutics against multidrug-resistant ESKAPE pathogens, running through April 2031); hybrid mRNA vaccine technologies for HIV and SARS-CoV-2 ($3.56 million NIAID award for enveloped virus-like particle vaccine technology, through August 2029); and targeted small-molecule recruitment to suppress HIV reactivation. In cardiovascular research, Gladstone pursues machine-learning driven discovery of noncoding variants in congenital heart disease ($925 thousand NHLBI award through April 2030) and epigenomic mechanisms of cardiac fibrosis ($1.585 million NHLBI award through May 2029). The institute also holds significant aging and longevity research portfolios addressing vitamin B3 therapies for mitochondrial disease, hypoxia therapy for metabolic dysfunction, and mechanistic links between APOE4 and tau in network dysfunction.

Activity has grown substantially. The institute received 25 awards in 2026 (year-to-date as of October), 49 in 2025, 44 in 2024, 32 in 2023, and 35 in 2022—indicating a rebound after 2022-2023 from 44 peak awards in 2024. Within the next twenty-four months, 34 awards carrying $31 thousand in combined potential value reach completion, presenting recompete opportunity. The institute's grant portfolio, however, carries significant overhead from obligated funds substantially exceeding potential values across the award set, reflecting the long-running nature of multi-year NIH R01 and P-series grants.

Subcontract partnerships are extensive. Gladstone receives sub-awards under prime grants led by the University of California San Francisco (cardiovascular phenotyping, HIV cohort research, Long COVID immune characterization), Stanford University (single-cell epigenomics and ArchR software maintenance), Columbia University and the Trustees of the University of Pennsylvania (HIV transcriptional dynamics, ALS pathomechanisms), Rutgers University (iPSC-derived brain models in Down syndrome-related Alzheimer's disease), and the University of Washington (Ebola host-virus interactions). The institute also serves as prime grantee with sub-recipients including Rush University Medical Center (vascular-immune mechanisms of cerebral amyloid angiopathy under a $10.847 million NIA award through August 2027) and Massachusetts General Hospital (HIV vaccine development).

Gladstone's federal engagement is research-execution focused rather than contract-based. The institute manages core laboratory facilities—flow cytometry, genomics, bioinformatics, stem-cell engineering, viral assay—that support both its own investigator-initiated grants and collaborative projects. The organization has held continuous NIH funding since registration in SAM in 2003 and demonstrates sustained competitiveness in competitive merit review, particularly in translational neuroscience, virology, and cardiovascular biology where mechanistic innovation and biomarker discovery create clinical pathways.